REVIEWS
ORIGINAL ARTICLES

Uterine cervical cancer is among the main items of modern oncology. Determination of SCCA levels in blood serum of women with locally disseminated forms of uterine cervical cancer has a great significance for estimation the extent of lesions, tumor progression patterns, as well as treatment monitoring. During our study, we have determined that, before starting a specific treatment, all the patients with locally disseminated forms of cervical cancer had high serum levels of SCCA, along with suppressed anti-tumor immunity.Interestingly, high SCCA levels in blood serum proved to correlate with a decrease in anti-tumor immunity factors in those patients who showed a negative dynamics of tumor progression within one year after the therapy was performed. Meanwhile, the patients with positive post-treatment dynamics exhibited a significant decrease of SCCA levels over a year after therapy, as compared with appropriate pre-treatment values, accompanied by increase in anti-tumor immunity markers in these cases.
SHORT COMMUNICATIONS
In present work, we studied cytokine levels and performed analysis of some immunologic parameters in the patients with chronic lymphocytic leukemia (CLL) before and after treatment with monoclonal anti-CD52 antibody (alemtuzumab). In comparison with a control group, the CLL patients before alemtuzumab treatment showed a significant decrease in relative contents of CD3+ and CD4+ lymphocytes, CD4+/CD8+ T cells, diminished IFNγ and IL-4 levels, and a trend for TNFα increase. After ceasing the alemtuzumab treatment, the patients with CLL exhibited a significant decrease in absolute amounts of mature T-lymphocytes, CD4+, CD8+, CD20+ cells, as well as decreased relative contents of CD16+ lymphocytes. A sufficient post-treatment drop of serum IL-2 concentrations and a trend for serum TNFα and IFNγ decrease were also observed, as compared with pre-treatment values. The changes revealed may be connected with an additional immunosuppressive effect of alemtuzumab. The dynamics of cytokine levels and immunological parameters associated with alemtuzumab treatment is indicative for a weakening of cell-mediated immunity, thus resulting into a potential risk of infectious complications.
OBITUARY
ANNIVERSARY
ISSN 2313-741X (Online)